Invention Grant
- Patent Title: Use of CXCL12 for therapy after prostate surgery
-
Application No.: US16637498Application Date: 2018-08-10
-
Publication No.: US11654181B2Publication Date: 2023-05-23
- Inventor: James K. Williams
- Applicant: Wake Forest University Health Sciences
- Applicant Address: US NC Winston-Salem
- Assignee: Wake Forest University Health Sciences
- Current Assignee: Wake Forest University Health Sciences
- Current Assignee Address: US NC Winston-Salem
- Agency: Myers Bigel, P.A.
- International Application: PCT/US2018/046156 2018.08.10
- International Announcement: WO2019/032930A 2019.02.14
- Date entered country: 2020-02-07
- Main IPC: A61K38/19
- IPC: A61K38/19 ; A61P15/10 ; A61K9/00 ; A61K48/00
Abstract:
This invention relates to C-X-C motif chemokine 12 (CXCL12), also known as stromal cell-derived factor 1 (SDF-1), vectors encoding the same, and methods of using the same for a male subject that has undergone prostate surgery to treat urological symptoms of the surgery.
Public/Granted literature
- US20200215160A1 THE USE OF CXCL12 FOR THERAPY AFTER PROSTATE SURGERY Public/Granted day:2020-07-09
Information query
IPC分类:
